Journal ArticleDOI
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Björn Dahlöf,Richard B. Devereux,Sverre E. Kjeldsen,Stevo Julius,Gareth Beevers,Ulf de Faire,Frej Fyhrquist,Hans Ibsen,Krister Kristiansson,Ole Lederballe-Pedersen,Lars H Lindholm,Markku S. Nieminen,Per Omvik,Suzanne Oparil,Hans Wedel +14 more
TLDR
Losartan prevents more cardiovascular morbidity and death than atenolol for a similar reduction in blood pressure and is better tolerated, while new-onset diabetes was less frequent with losartan.About:
This article is published in The Lancet.The article was published on 2002-03-23. It has received 5380 citations till now. The article focuses on the topics: Angiotensin II & Atenolol.read more
Citations
More filters
Journal ArticleDOI
The adipose-tissue renin–angiotensin–aldosterone system: role in the metabolic syndrome?
Stefan Engeli,Petra Schling,K. Gorzelniak,Michael Boschmann,Jürgen Janke,Gérard Ailhaud,Michèle Teboul,Florence Massiera,Arya M. Sharma,Arya M. Sharma +9 more
TL;DR: The beneficial effects of ACE-inhibition and angiotensin-receptor blockade on the development of type 2 diabetes in large clinical trials suggest a pathophysiological role of the adipose-tissue renin-angiotens in system in the metabolic syndrome.
Journal ArticleDOI
Prevention of Obesity and Insulin Resistance in Mice Lacking Plasminogen Activator Inhibitor 1
Li-Jun Ma,Su Li Mao,Kevin L. Taylor,Talerngsak Kanjanabuch,YouFei Guan,YaHua Zhang,Nancy J. Brown,Larry L. Swift,Owen P. McGuinness,David H. Wasserman,Douglas E. Vaughan,Agnes B. Fogo +11 more
TL;DR: The data suggest that PAI-1 may not merely increase in response to obesity and insulin resistance, but may have a direct causal role in obesity and IGF-1 resistance.
Journal ArticleDOI
Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
Koon K. Teo,Salim Yusuf,Peter Sleight,Craig S. Anderson,Farouk Mookadam,Barbara Ramos,Lutz Hilbrich,Janice Pogue,Helmut Schumacher,Ontarget,Transcend Investigators +10 more
TL;DR: The Telmisartan Randomized AssessmeNt Study in aCE iNtolerant subjects with cardiovascular Disease (TRANSCEND) will determine if tel Misartan is superior to placebo in patients who are intolerant of ACE inhibitors.
Journal ArticleDOI
Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin–angiotensin–aldosterone system inhibitors involving 158 998 patients
Laura C van Vark,Michel E. Bertrand,K. Martijn Akkerhuis,Jasper J. Brugts,Kim Fox,Jean-Jacques Mourad,Eric Boersma +6 more
TL;DR: In patients with hypertension, treatment with an ACE inhibitor results in a significant further reduction in all-cause mortality, and the widespread use of ACE inhibitors may result in an important gain in lives saved.
Journal ArticleDOI
Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction ☆: Results of the New York heart failure registry
Marc Klapholz,Matthew S. Maurer,April M. Lowe,Frank C. Messineo,Jay S. Meisner,Judith E. Mitchell,Jill Kalman,Robert A. Phillips,Richard M. Steingart,Edward J. Brown,Robert Berkowitz,Robert Moskowitz,Anita Soni,Donna Mancini,Rachel Bijou,Khashayar Sehhat,Nikita Varshneya,Marrick L. Kukin,Stuart D. Katz,Lynn A. Sleeper,Thierry H. Le Jemtel +20 more
TL;DR: Patients hospitalized for heart failure with a normal ejection fraction are most often chronically incapacitated elderly women with a history of hypertension and increased LV mass, and reasons for clinical decompensation are identified in only one-half of patients.
References
More filters
Journal ArticleDOI
Effects of an angiotensin-converting -enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
TL;DR: Ramipril significantly reduces the rates of death, myocardial infarction, and stroke in a broad range of high-risk patients who are not known to have a low ejection fraction or heart failure.
Journal ArticleDOI
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
Barry M. Brenner,Mark E. Cooper,Dick de Zeeuw,William F. Keane,William E. Mitch,Hans-Henrik Parving,Giuseppe Remuzzi,Steven M. Snapinn,Zhonxin Zhang,Shahnaz Shahinfar +9 more
TL;DR: Losartan conferred significant renal benefits in patients with type 2 diabetes and nephropathy, and it was generally well tolerated.
Journal ArticleDOI
Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial
Lennart Hansson,Lars H Lindholm,Leo Niskanen,Jan Lanke,Thomas Hedner,Anders Niklason,Kimmo Luomanmäki,Björn Dahlöf,Ulf de Faire,Claes Mörlin,Bengt E. Karlberg,P. O. Wester,Jan-Erik Björck +12 more
TL;DR: Captopril and conventional treatment did not differ in efficacy in preventing cardiovascular morbidity and mortality and the difference in stroke risk was probably due to the lower levels of blood pressure obtained initially in previously treated patients randomised to conventional therapy.
Journal ArticleDOI
An updated coronary risk profile. A statement for health professionals.
TL;DR: Using a simple worksheet, a patient's 5- and 10-year CHD risks can be estimated using components of the profile selected because they are objective and strongly and independently related to CHD.
Journal ArticleDOI
Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration
TL;DR: Strong evidence of benefits of ACE inhibitors and calcium antagonists is provided by the overviews of placebo-controlled trials, and data from continuing trials of blood-pressure-lowering drugs will substantially increase the evidence available about any real differences that might exist between regimens.
Related Papers (5)
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
Curt D. Furberg,Jackson T. Wright,Barry R. Davis,Jeffrey A. Cutler,Michael H. Alderman,Henry R. Black,William C. Cushman,Richard H. Grimm,L. Julian Haywood,Frans H. H. Leenen,Suzanne Oparil,Jeffrey L. Probstfield,Paul K. Whelton,Chuke Nwachuku,David Gordon,Michael A. Proschan,Paula Einhom,Charles E. Ford,Linda B. Piller,I. Kay Dunn,David C. Goff,Sara L. Pressel,Judy Bettencourt,Barbara DeLeon,Lara M. Simpson,Joe Blanton,Therese S. Geraci,Sandra M. Walsh,Christine Nelson,Mahboob Rahman,Anne Juratovac,Robert Pospisil,Lillian Carroll,Sheila Sullivan,Jeanne Russo,Gail Barone,Rudy Christian,Sharon Feldman,Tracy Lucente,David A. Calhoun,Kim Jenkins,Peggy McDowell,Janice Johnson,Connie Kingry,Juan Alzate,Karen L. Margolis,Leslie Ann Holland-Klemme,Brenda Jaeger,Jeff D. Williamson,Gail T. Louis,Pamela Ragusa,Angela Williard,R. L Sue Ferguson,Joanna Tanner,John H. Eckfeldt,Richard S. Crow,John Pelosi +56 more